Methods: 174 patients were treated with Shenyanling Granule. The levels of serum TC, TG, LDL-C, HDL-C and apo-A, apo-B were observed before and after the treatment.

方法：174例患者全部服用肾炎灵颗粒冲剂进行治疗，观察治疗前后其血清胆固醇、三酰甘油、高密度脂蛋白、低密度脂蛋白及载脂蛋白a、B的水平。

youdao

KYNAMRO, given as a 200 mg weekly subcutaneous injection, has been approved as an adjunct to lipid-lowering medications and diet to reduce low density lipoprotein-cholesterol (LDL-C), apolipoprotein B (Apo B), total cholesterol (TC), and non-high density lipoprotein-cholesterol (non HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH).

FORBES: FDA Approves Mipomersen For Homozygous Familial Hypercholesterolemia